AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) Files An 8-K Submission of Matters to a Vote of Security Holders

AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.

Story continues below

Submission of Matters to a Vote of Security Holders.

On June 8, 2018, Audentes Therapeutics, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders and the following proposals were adopted:

1.

Election of two Class II directors, Louis Lange and Kush Parmar, each to serve three-year terms through the third annual meeting of stockholders following the 2018 annual meeting and until a successor has been elected and qualified or until earlier resignation or removal:

Nominees

Shares For

SharesWithheld

Broker Non-Votes

Louis Lange

27,350,557

5,750,597

1,722,219

Kush Parmar

28,208,995

4,892,159

1,722,219

2.

Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018:

Shares For

SharesAgainst

Shares Abstaining

34,758,553

1,515

63,305


About AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD)

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues.

An ad to help with our costs